Gilder Gagnon Howe & Co. LLC raised its position in Glaukos Corp. (NYSE:GKOS) by 41.2% during the third quarter, Holdings Channel reports. The fund owned 1,612,194 shares of the company’s stock after buying an additional 470,354 shares during the period. Gilder Gagnon Howe & Co. LLC owned 4.88% of Glaukos Corp. worth $60,844,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in GKOS. Essex Investment Management Co. LLC purchased a new position in Glaukos Corp. during the second quarter valued at approximately $614,000. BP PLC purchased a new position in Glaukos Corp. during the second quarter valued at approximately $426,000. CAM Group Holding A S purchased a new position in Glaukos Corp. during the second quarter valued at approximately $2,187,000. Bank of New York Mellon Corp increased its position in Glaukos Corp. by 182.7% in the second quarter. Bank of New York Mellon Corp now owns 82,790 shares of the company’s stock valued at $2,413,000 after buying an additional 53,503 shares during the last quarter. Finally, California State Teachers Retirement System increased its position in Glaukos Corp. by 134.5% in the second quarter. California State Teachers Retirement System now owns 35,052 shares of the company’s stock valued at $1,022,000 after buying an additional 20,107 shares during the last quarter. Hedge funds and other institutional investors own 77.65% of the company’s stock.
Shares of Glaukos Corp. (NYSE:GKOS) opened at 38.73 on Thursday. The company has a market cap of $1.30 billion, a PE ratio of 679.47 and a beta of 1.29. Glaukos Corp. has a one year low of $14.25 and a one year high of $41.00. The firm’s 50-day moving average is $34.83 and its 200-day moving average is $33.98.
Glaukos Corp. (NYSE:GKOS) last announced its quarterly earnings results on Thursday, November 10th. The company reported $0.03 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.00 by $0.03. The company earned $29.60 million during the quarter, compared to the consensus estimate of $27.21 million. Glaukos Corp. had a net margin of 2.07% and a return on equity of 2.05%. The firm’s quarterly revenue was up 55.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.07) earnings per share. On average, equities analysts anticipate that Glaukos Corp. will post $0.12 EPS for the current year.
Several equities analysts recently commented on the company. Stifel Nicolaus reiterated a “hold” rating on shares of Glaukos Corp. in a research note on Tuesday, September 27th. Cantor Fitzgerald reiterated a “buy” rating and issued a $41.00 price objective on shares of Glaukos Corp. in a research note on Sunday, September 25th. Zacks Investment Research upgraded Glaukos Corp. from a “hold” rating to a “strong-buy” rating and set a $44.00 price objective on the stock in a research note on Wednesday, October 5th. Finally, Wells Fargo & Co. assumed coverage on Glaukos Corp. in a research note on Thursday, October 27th. They issued an “outperform” rating on the stock. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average price target of $40.67.
In related news, insider Chris M. Calcaterra sold 18,136 shares of the firm’s stock in a transaction that occurred on Friday, January 13th. The shares were sold at an average price of $40.01, for a total value of $725,621.36. Following the sale, the insider now owns 254,413 shares in the company, valued at $10,179,064.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Chris M. Calcaterra sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, October 24th. The stock was sold at an average price of $36.01, for a total transaction of $720,200.00. Following the completion of the sale, the insider now owns 260,000 shares in the company, valued at approximately $9,362,600. The disclosure for this sale can be found here. Corporate insiders own 36.80% of the company’s stock.
Glaukos Corp. Company Profile
Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide.
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corp. (NYSE:GKOS).